Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29589464 | 0.80 | EPHX1 (0.45) | BRD4EPHX1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL20993453 | 0.80 | EPHX1 (0.45) | BRD4EPHX1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL771850 | 0.80 | GAA (0.53) | BRD4EPHX1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL6495220 | 0.80 | EPHX1 (0.45) | BRD4EPHX1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL7974809 | 0.79 | EPHX1 (0.42) | BRD4EPHX1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL1267093 | 0.79 | GAA (0.62) | L3MBTL1THRBATMGAATSHR | |
| SCHEMBL18697087 | 0.78 | EPHX1 (0.44) | BRD4EPHX1CHRNB2CHRNA4CHRNB4 | |
| Hydrochloric Acid SCHEMBL12494569 | 0.78 | GAA (0.51) | BRD4EPHX1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL1564369 | 0.78 | EPHX1 (0.44) | BRD4EPHX1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL12321755 | 0.78 | EPHX1 (0.44) | BRD4EPHX1CHRNB2CHRNA4CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667635-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2023-06-06 | — | — | US | claimed |
| US-20220009921-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2022-01-13 | — | — | US | claimed |
| US-20180244672-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2018-08-30 | — | — | US | claimed |
| EP-3259270-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | Incyte Corporation (US) | 2017-12-27 | — | — | EP | claimed |
| WO-2016134314-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION (US) | 2016-08-25 | — | — | WO | claimed |
| US-20160244448-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2016-08-25 | — | — | US | claimed |
| EP-1817036-B1 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMA (US) | 2012-07-04 | — | — | EP | claimed |
| CN-101784516-A | Dipeptide analogs as coagulation factor inhibitors | BRISTOL MYERS SQUIBB CO | 2010-07-21 | — | — | CN | claimed |
| EP-1817036-A2 | MODULATORS OF MUSCARINIC RECEPTORS | Vertex Pharmaceuticals Incorporated (US) | 2007-08-15 | — | — | EP | claimed |
| US-20060270653-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-11-30 | — | — | US | claimed |
| WO-2006058303-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | claimed |
| CN-113024547-B | Bicyclic heterocycles as FGFR4 inhibitors | 因赛特控股公司 | 2023-07-21 | — | — | CN | disclosed |
| US-11667635-B2 | Bicyclic heterocycles as FGFR4 inhibitors | INCYTE CORPORATION (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220009921-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | INCYTE CORPORATION | 2022-01-13 | — | — | US | disclosed |
| CN-113024547-A | Bicyclic heterocycles as FGFR4 inhibitors | 因赛特公司 | 2021-06-25 | — | — | CN | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20060270653-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-11-30 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| WO-2006058303-A2 | MODULATORS OF MUSCARINIC RECEPTORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244448-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | BRD4 13/4885EPHX1 1353/4885CHRNB2 4783/4885 |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | BRD4 446/4885EPHX1 3653/4885CHRNB2 4884/4885 |
| US-11667635-B2 | Bicyclic heterocycles as FGFR4 inhibitors | FGFR4, FGFR1, FGFR3 | BRD4 13/4885EPHX1 1353/4885CHRNB2 4783/4885 |
| US-20220009921-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | BRD4 13/4885EPHX1 1353/4885CHRNB2 4783/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | BRD4 357/4885EPHX1 2426/4885CHRNB2 4885/4885 |
| US-20180244672-A1 | BICYCLIC HETEROCYCLES AS FGFR4 INHIBITORS | FGFR4, FGFR1, FGFR3 | BRD4 13/4885EPHX1 1353/4885CHRNB2 4783/4885 |
| US-20060270653-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | BRD4 764/4885EPHX1 872/4885CHRNB2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.